Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment

Jeffrey N. Joyce, T. C. Der, Lynn Renish, Tracy Osredkar, Diane Hagner, Maria Reploge, Shinichi Sakakibara, Shuichi Ueda

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

In Parkinson's disease (PD) and animal models of parkinsonism the destruction of nigrostriatal (NSB) system results in a marked loss of the dopamine D3 receptor and mRNA in the islands of Calleja (ICj) and the nucleus accumbens shell (NAS). In animal models, it has been reported that both measures are elevated by repeated intermittent administration of L-dopa. However, a large proportion of PD cases are resistant to L-dopa-induced elevation of D3 receptor number. The zitter mutant (Zi/Zi) rat replicates the slow progressive degeneration of the NSB observed in PD and also exhibits a loss of D3 receptor number in the NAS or ICj. To test if this could be reversed with subchronic L-dopa treatment, injections of carbidopa (10 mg/kg ip) were followed an hour later with injection of L-dopa (100 mg/kg ip) twice a day for 10 days. In control Sprague-Dawley (SD) and zitter heterozygote (Zi/-) rats that do not show a loss of D3 receptors with vehicle treatment, L-dopa produced no change in D3 receptor number or in DA terminal density as measured by dopamine transporter (DAT) binding and tyrosine hydroxylase immunoautoradiography (TH-IR). There was a marked loss of DAT and TH-IR in caudate-putamen (CPu) and NA, as well as D3 receptors in NAS and ICj in Zi/Zi rats but no further change with L-dopa treatment. To determine if the resistance to L-dopa-induced increase in D3 receptor was due to a deficiency in expression of cortical BDNF or its receptor, TrkB, in CPu and NAS, we examined BDNF mRNA by ISHH in frontal cortex and TrkB mRNA in frontal cortex, CPu, and NA. The loss of the NSB in the Zi/Zi did not alter levels of BDNF or TrkB mRNA, nor did L-dopa administration alter levels BDNF or TrkB mRNA. Thus, unlike in 6-hydroxydopamine-treated rats, in Zi/Zi rats administered L-dopa does not reverse the loss of BDNF mRNA or lead to an elevation of D3 receptor number.

Original languageEnglish
Pages (from-to)178-189
Number of pages12
JournalExperimental Neurology
Volume187
Issue number1
DOIs
Publication statusPublished - 2004 May
Externally publishedYes

Fingerprint

Levodopa
Brain-Derived Neurotrophic Factor
Islands of Calleja
Nucleus Accumbens
Messenger RNA
Putamen
Parkinson Disease
Dopamine Plasma Membrane Transport Proteins
Therapeutics
Tyrosine 3-Monooxygenase
Frontal Lobe
Animal Models
trkB Receptor
Dopamine D3 Receptors
Carbidopa
Injections
Caudate Nucleus
Oxidopamine
Parkinsonian Disorders
Heterozygote

Keywords

  • Nucleus accumbens
  • Parkinson's disease
  • Striatum
  • Substantia nigra
  • Tyrosine hydroxylase
  • Ventral tegmental area

ASJC Scopus subject areas

  • Neurology
  • Neuroscience(all)

Cite this

Joyce, J. N., Der, T. C., Renish, L., Osredkar, T., Hagner, D., Reploge, M., ... Ueda, S. (2004). Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment. Experimental Neurology, 187(1), 178-189. https://doi.org/10.1016/j.expneurol.2004.01.012

Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment. / Joyce, Jeffrey N.; Der, T. C.; Renish, Lynn; Osredkar, Tracy; Hagner, Diane; Reploge, Maria; Sakakibara, Shinichi; Ueda, Shuichi.

In: Experimental Neurology, Vol. 187, No. 1, 05.2004, p. 178-189.

Research output: Contribution to journalArticle

Joyce, JN, Der, TC, Renish, L, Osredkar, T, Hagner, D, Reploge, M, Sakakibara, S & Ueda, S 2004, 'Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment', Experimental Neurology, vol. 187, no. 1, pp. 178-189. https://doi.org/10.1016/j.expneurol.2004.01.012
Joyce, Jeffrey N. ; Der, T. C. ; Renish, Lynn ; Osredkar, Tracy ; Hagner, Diane ; Reploge, Maria ; Sakakibara, Shinichi ; Ueda, Shuichi. / Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment. In: Experimental Neurology. 2004 ; Vol. 187, No. 1. pp. 178-189.
@article{7d2e851ee163479a80cee0d84cc5f656,
title = "Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment",
abstract = "In Parkinson's disease (PD) and animal models of parkinsonism the destruction of nigrostriatal (NSB) system results in a marked loss of the dopamine D3 receptor and mRNA in the islands of Calleja (ICj) and the nucleus accumbens shell (NAS). In animal models, it has been reported that both measures are elevated by repeated intermittent administration of L-dopa. However, a large proportion of PD cases are resistant to L-dopa-induced elevation of D3 receptor number. The zitter mutant (Zi/Zi) rat replicates the slow progressive degeneration of the NSB observed in PD and also exhibits a loss of D3 receptor number in the NAS or ICj. To test if this could be reversed with subchronic L-dopa treatment, injections of carbidopa (10 mg/kg ip) were followed an hour later with injection of L-dopa (100 mg/kg ip) twice a day for 10 days. In control Sprague-Dawley (SD) and zitter heterozygote (Zi/-) rats that do not show a loss of D3 receptors with vehicle treatment, L-dopa produced no change in D3 receptor number or in DA terminal density as measured by dopamine transporter (DAT) binding and tyrosine hydroxylase immunoautoradiography (TH-IR). There was a marked loss of DAT and TH-IR in caudate-putamen (CPu) and NA, as well as D3 receptors in NAS and ICj in Zi/Zi rats but no further change with L-dopa treatment. To determine if the resistance to L-dopa-induced increase in D3 receptor was due to a deficiency in expression of cortical BDNF or its receptor, TrkB, in CPu and NAS, we examined BDNF mRNA by ISHH in frontal cortex and TrkB mRNA in frontal cortex, CPu, and NA. The loss of the NSB in the Zi/Zi did not alter levels of BDNF or TrkB mRNA, nor did L-dopa administration alter levels BDNF or TrkB mRNA. Thus, unlike in 6-hydroxydopamine-treated rats, in Zi/Zi rats administered L-dopa does not reverse the loss of BDNF mRNA or lead to an elevation of D3 receptor number.",
keywords = "Nucleus accumbens, Parkinson's disease, Striatum, Substantia nigra, Tyrosine hydroxylase, Ventral tegmental area",
author = "Joyce, {Jeffrey N.} and Der, {T. C.} and Lynn Renish and Tracy Osredkar and Diane Hagner and Maria Reploge and Shinichi Sakakibara and Shuichi Ueda",
year = "2004",
month = "5",
doi = "10.1016/j.expneurol.2004.01.012",
language = "English",
volume = "187",
pages = "178--189",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment

AU - Joyce, Jeffrey N.

AU - Der, T. C.

AU - Renish, Lynn

AU - Osredkar, Tracy

AU - Hagner, Diane

AU - Reploge, Maria

AU - Sakakibara, Shinichi

AU - Ueda, Shuichi

PY - 2004/5

Y1 - 2004/5

N2 - In Parkinson's disease (PD) and animal models of parkinsonism the destruction of nigrostriatal (NSB) system results in a marked loss of the dopamine D3 receptor and mRNA in the islands of Calleja (ICj) and the nucleus accumbens shell (NAS). In animal models, it has been reported that both measures are elevated by repeated intermittent administration of L-dopa. However, a large proportion of PD cases are resistant to L-dopa-induced elevation of D3 receptor number. The zitter mutant (Zi/Zi) rat replicates the slow progressive degeneration of the NSB observed in PD and also exhibits a loss of D3 receptor number in the NAS or ICj. To test if this could be reversed with subchronic L-dopa treatment, injections of carbidopa (10 mg/kg ip) were followed an hour later with injection of L-dopa (100 mg/kg ip) twice a day for 10 days. In control Sprague-Dawley (SD) and zitter heterozygote (Zi/-) rats that do not show a loss of D3 receptors with vehicle treatment, L-dopa produced no change in D3 receptor number or in DA terminal density as measured by dopamine transporter (DAT) binding and tyrosine hydroxylase immunoautoradiography (TH-IR). There was a marked loss of DAT and TH-IR in caudate-putamen (CPu) and NA, as well as D3 receptors in NAS and ICj in Zi/Zi rats but no further change with L-dopa treatment. To determine if the resistance to L-dopa-induced increase in D3 receptor was due to a deficiency in expression of cortical BDNF or its receptor, TrkB, in CPu and NAS, we examined BDNF mRNA by ISHH in frontal cortex and TrkB mRNA in frontal cortex, CPu, and NA. The loss of the NSB in the Zi/Zi did not alter levels of BDNF or TrkB mRNA, nor did L-dopa administration alter levels BDNF or TrkB mRNA. Thus, unlike in 6-hydroxydopamine-treated rats, in Zi/Zi rats administered L-dopa does not reverse the loss of BDNF mRNA or lead to an elevation of D3 receptor number.

AB - In Parkinson's disease (PD) and animal models of parkinsonism the destruction of nigrostriatal (NSB) system results in a marked loss of the dopamine D3 receptor and mRNA in the islands of Calleja (ICj) and the nucleus accumbens shell (NAS). In animal models, it has been reported that both measures are elevated by repeated intermittent administration of L-dopa. However, a large proportion of PD cases are resistant to L-dopa-induced elevation of D3 receptor number. The zitter mutant (Zi/Zi) rat replicates the slow progressive degeneration of the NSB observed in PD and also exhibits a loss of D3 receptor number in the NAS or ICj. To test if this could be reversed with subchronic L-dopa treatment, injections of carbidopa (10 mg/kg ip) were followed an hour later with injection of L-dopa (100 mg/kg ip) twice a day for 10 days. In control Sprague-Dawley (SD) and zitter heterozygote (Zi/-) rats that do not show a loss of D3 receptors with vehicle treatment, L-dopa produced no change in D3 receptor number or in DA terminal density as measured by dopamine transporter (DAT) binding and tyrosine hydroxylase immunoautoradiography (TH-IR). There was a marked loss of DAT and TH-IR in caudate-putamen (CPu) and NA, as well as D3 receptors in NAS and ICj in Zi/Zi rats but no further change with L-dopa treatment. To determine if the resistance to L-dopa-induced increase in D3 receptor was due to a deficiency in expression of cortical BDNF or its receptor, TrkB, in CPu and NAS, we examined BDNF mRNA by ISHH in frontal cortex and TrkB mRNA in frontal cortex, CPu, and NA. The loss of the NSB in the Zi/Zi did not alter levels of BDNF or TrkB mRNA, nor did L-dopa administration alter levels BDNF or TrkB mRNA. Thus, unlike in 6-hydroxydopamine-treated rats, in Zi/Zi rats administered L-dopa does not reverse the loss of BDNF mRNA or lead to an elevation of D3 receptor number.

KW - Nucleus accumbens

KW - Parkinson's disease

KW - Striatum

KW - Substantia nigra

KW - Tyrosine hydroxylase

KW - Ventral tegmental area

UR - http://www.scopus.com/inward/record.url?scp=1842663404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842663404&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2004.01.012

DO - 10.1016/j.expneurol.2004.01.012

M3 - Article

C2 - 15081599

AN - SCOPUS:1842663404

VL - 187

SP - 178

EP - 189

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 1

ER -